Arvinas

Arvinas (operating at arvinas.com) is a clinical-stage biotechnology company pioneering **targeted protein degradation therapeutics**, a groundbreaking approach to treating debilitating and life-threatening diseases. Founded with a mission to redefine drug development, the company leverages proprietary technology to degrade disease-causing proteins directly within cells—a paradigm shift from traditional small-molecule or antibody-based therapies. By harnessing its platform, Arvinas enables precise modulation of pathological proteins linked to cancer, neurodegenerative disorders, and autoimmune diseases, offering potential cures where conventional treatments fall short. Patients and researchers benefit from a new class of drugs with enhanced specificity and reduced off-target effects. Backed by over **$462 million in funding** as of mid-2026, including a recent **$55 million Series C round led by Nextech Invest**, Arvinas is accelerating its lead oncology programs into clinical trials while expanding its early-stage pipeline.